Patents by Inventor Martine Peeters

Martine Peeters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9765406
    Abstract: The oligonucleotide of sequence SEQ ID No.1: 5?-CTAGAGATCCCTCAGA-3?, and the complementary sequence thereof of sequence SEQ ID No.2: 5?-TCTGAGGGATCTCTAG-3? useful as probes to detect and quantify all HIV-1 circulating forms and their precursors SIVcpz/SIVgor.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: September 19, 2017
    Assignee: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)
    Inventors: Martine Peeters, Lucie Etienne
  • Publication number: 20150275316
    Abstract: The oligonucleotide of sequence SEQ ID No 1: 5?-CTAGAGATCCCTCAGA-3?, and the complementary sequence thereof of sequence SEQ ID No 2: 5?-TCTGAGGGATCTCTAG-3? useful as probes to detect and quantify all HIV-1 circulating forms and their precursors SIVcpz/SIVgor.
    Type: Application
    Filed: November 8, 2013
    Publication date: October 1, 2015
    Inventors: Martine Peeters, Lucie Etienne
  • Publication number: 20030180759
    Abstract: The current invention relates to new HIV-1 group O antigens, nucleic acids encoding them, and the use of said antigens and/or nucleic acids as reagents in the diagnosis and prophylaxis of AIDS. It also relates to new HIV-1 group O strains comprising these antigens.
    Type: Application
    Filed: December 16, 2002
    Publication date: September 25, 2003
    Applicant: INNOGENETICS N.V.
    Inventors: Eric Delaporte, Martine Peeters, Eric Saman, Marleen Vanden Haesevelde
  • Patent number: 6511801
    Abstract: The claimed invention relates to an HIV-1 group O envelope antigen comprising SEQ ID NO: 100, and the use of said antigen as a reagent in the diagnosis of HIV-1 group O infection, and a kit therefore.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: January 28, 2003
    Assignee: Innogenetics, N.V.
    Inventors: Eric DeLaporte, Martine Peeters, Eric Saman, Marleen Vanden Haesevelde
  • Patent number: 5624795
    Abstract: The present invention relates to a retrovirus isolated from a chimpanzee and designated as SIV.sub.cpz-ant and to variants of this virus, having the following essential morphological and immunological properties: the virus exhibits a tropism for T4 lymphocytes, the virus does not exhibit cytopathic effect with the formation of giant cells in the lymphocytes that it infects, the virus has a diameter of approximately 130 nm, the virus possesses a magnesium dependent reverse transcriptase activity, it can be cultivated in T4 receptor-bearing immortalized cell-lines, lysates of the virus containing a p27 protein that is immunologically distinct from the p25 of HIV-1 and p19 protein of HTLV-1 on Western Blot, lysates of the virus containing a gp140 protein which is immunologically distinct from the gp120 of HIV-1 and gp140 of HTLV-1 by Western Blot analysis, the lysate of the virus contains an additional transmembrane glycoprotein with a molecular weight of 44,000 to 50,000 kD.
    Type: Grant
    Filed: February 11, 1993
    Date of Patent: April 29, 1997
    Assignee: Innogenetics, N.V.
    Inventors: Peter Piot, Guido Van Der Groen, Eric DeLaporte, Martine Peeters